Dr. Martina Lehnert
Burger S, Lehnert M, Ludwig H. Erythropoiesis stimulating proteins for the treatment of anemia in cancer patients. Ther Umsch. 2010 May;67(5):271-6.
Lehnert M, Ludwig H, Zojer N. Update on the rational use of 90Y-ibritumomab tiuxetan in the treatment of follicular lymphoma. Review. OncoTargets and Therapy 2009;2:199-08.
Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant MF, Filipits M, Austrian Breast and Colorectal Cancer Study Group. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin Cancer Res. 2008 Mar 15;14(6):1767-74.
Herberger B, Puhalla H, Lehnert M, Wrba F, Novak S, Brandstetter A, Gruenberger B, Gruenberger T, Pirker R, Filipits M. Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res. 2007 Aug 15;13(16):4795-9.
Puhalla H, Wrba F, Kandioler D, Lehnert M, Huynh A, Gruenberger T, Tamandl D, Filipits M. Expression of p21(Wafl/Cip1), p57(Kip2) and HER2/neu in patients with gallbladder cancer. Anticancer Res. 2007 May-Jun;27(3B):1679-84.
Pirker R, Lehnert M, Minar W. Once-weekly epoetin beta (30,000 IU) in anemic patients with lung cancer receiving chemotherapy. Lung Cancer. 2007 Jan;55(1):89-94. Epub 2006 Nov 3.